Treatment outcomes of visceral leishmaniasis in Ethiopia from 2001 to 2017: a systematic review and meta-analysis

Table 2 Visceral leishmaniasis -HIV co-infection and treatment failure and mortality

	Studies	HIV+ (Sample/ Total)	HIV- (Sample/ Total)	OR (95% CI)	P-value	I ²
EOT
Overall treatment failure	5 studies [18, 21, 22, 28, 29]	67/473	0/781	20.35 (4.87–85.03)	0.600	0.00
SSG treatment failure	3 studies [18, 28, 29]	1/119	0/411	5.55 (0.68–45.57)	0.912	0.00
Overall mortality	6 studies [18, 20,21,22, 28, 29]	71/523	39/1029	4.14 (2.48–6.89)	0.216	29.16
SSG mortality	3 studies [18, 28, 29]	25/119	19/411	5.79 (2.39–14.01)	0.195	38.79
6MFU
Overall treatment failure	3 studies [21, 28, 29]	43/158	7/362	12.65 (5.44–29.43)	0.641	0.00
SSG treatment failure	2 studies [28, 29]	7/58	1/224	18.39 (2.82–120.00)	0.489	0.00
Overall mortality	3 studies [21, 28, 29]	39/158	21/362	4.77 (1.30–17.43)	*	78.96
SSG mortality	2 studies [28, 29]	16/58	12/224	7.03 (1.32–37.33)	0.05	73.86

Note: OR odds ratio, CI confidence interval, EOT End of treatment, 6MFU 6 months follow-up, SSG sodium stibogluconate, *p-value < 0.005

ISSN: 2049-9957